{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T00:25:30Z","timestamp":1794097530667,"version":"4.8.0"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6S","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are an increasingly prescribed class of antidiabetic medications with expanded use in chronic weight management. Emerging literature has raised concerns regarding dermatologic adverse effects of GLP-1RAs, including various forms of alopecia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To evaluate the prevalence of GLP-1RA\u2013associated alopecia, differences among agents, and proposed underlying mechanisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS<\/jats:title>\n                    <jats:p>A scoping review of GLP-1RAs and alopecia was conducted using PubMed, including articles published up to April 2026.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Current literature presents conflicting evidence regarding the effects of GLP-1RAs on hair loss. Available data suggest an association between GLP-1RAs and telogen effluvium and androgenic alopecia, with risk potentially increasing with longer duration of use, greater weight loss, and higher doses, particularly with tirzepatide and semaglutide. Proposed mechanisms include weight loss\u2013related changes, alterations in dermal white adipose tissue, and hormonal influences, although their relative contributions remain unclear. Conversely, a smaller body of literature suggests improvement in inflammatory alopecia with GLP-1RA use, particularly among patients with metabolic dysfunction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Given the increasing use of GLP-1RAs, dermatology practitioners should be aware of their association with alopecia and consider patient counseling, monitoring, and proactive treatment in patients receiving GLP-1RA therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/dss.0000000000005176","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T09:00:41Z","timestamp":1780045241000},"page":"S67-S71","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["The Role of Glucagon-Like Peptide-1 Receptor Agonists in Hair Loss: Clinical Evidence and Proposed Mechanisms"],"prefix":"10.1097","volume":"52","author":[{"given":"Nikkia","family":"Zarabian","sequence":"first","affiliation":[{"name":"All authors are affiliated with the Department of Dermatology, George Washington University School of Medicine and Health, Sciences, Washington, District of Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Farah","sequence":"additional","affiliation":[{"name":"All authors are affiliated with the Department of Dermatology, George Washington University School of Medicine and Health, Sciences, Washington, District of Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Stines","sequence":"additional","affiliation":[{"name":"All authors are affiliated with the Department of Dermatology, George Washington University School of Medicine and Health, Sciences, Washington, District of Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Friedman","sequence":"additional","affiliation":[{"name":"All authors are affiliated with the Department of Dermatology, George Washington University School of Medicine and Health, Sciences, Washington, District of Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"R1-20260730","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1900\/RDS.2014.11.202","article-title":"Adverse effects of GLP-1 receptor agonists","volume":"11","author":"Filippatos","year":"2014","journal-title":"Rev Diabet Stud"},{"key":"R2-20260730","first-page":"e92454","article-title":"Hair loss associated with glucagon-like peptide-1 (GLP-1) receptor agonist use: a systematic review","volume":"17","author":"Alsuwailem","year":"2025","journal-title":"Cureus"},{"key":"R3-20260730","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1159\/000544023","article-title":"Dermatologic implications of glucagon-like peptide-1 receptor agonist medications","volume":"11","author":"Burke","year":"2025","journal-title":"Skin Appendage Disord"},{"key":"R4-20260730","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1007\/s10557-024-07613-w","article-title":"Risk of suicide, hair loss, and aspiration with GLP1-receptor agonists and other diabetic agents: a real-world pharmacovigilance study","volume":"39","author":"Nakhla","year":"2025","journal-title":"Cardiovasc Drugs Ther"},{"key":"R5-20260730","doi-asserted-by":"crossref","first-page":"e2540890","DOI":"10.1001\/jamanetworkopen.2025.40890","article-title":"Prescribing trends of glucagon-like peptide-1 receptor agonists for type 2 diabetes or obesity","volume":"8","author":"Li","year":"2025","journal-title":"JAMA Netw Open"},{"key":"R6-20260730","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/ijd.17246","article-title":"GLP-1 agonists and hair loss: a call for further investigation","volume":"63","author":"Desai","year":"2024","journal-title":"Int J Dermatol"},{"key":"R7-20260730","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/jdv.20512","article-title":"Exploring the hair loss risk in glucagon-like peptide-1 agonists: emerging concerns and clinical implications","volume":"39","author":"Buontempo","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R8-20260730","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1111\/jdv.20197","article-title":"Alopecia associated with the use of semaglutide and tirzepatide: a disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023","volume":"39","author":"Godfrey","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R9-20260730","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jdrv.2025.04.009","article-title":"Impact of glucagon-like peptide-1 receptor agonists on cutaneous events: a systematic review and meta-analysis","volume":"5","author":"Yu","year":"2025","journal-title":"JAAD Rev"},{"key":"R10-20260730","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jaad.2025.01.046","article-title":"Glucagon-like peptide-1 receptor agonist medications and hair loss: a retrospective cohort study","volume":"92","author":"Burke","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"R11-20260730","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jaad.2024.03.021","article-title":"Dermatologic findings associated with semaglutide use: a scoping review","volume":"91","author":"Tran","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"R12-20260730","first-page":"S0190-9622(26)00248-3","article-title":"Risk of new-onset hair loss with semaglutide and tirzepatide: a TriNetX cohort study","author":"Herrera","year":"2026","journal-title":"J Am Acad Dermatol"},{"key":"R13-20260730","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jdin.2026.01.014","article-title":"Increased risk of hair loss with GLP-1 receptor agonists: a real-world multicenter TriNetX cohort study","volume":"25","author":"Vidal","year":"2026","journal-title":"JAAD Int"},{"key":"R14-20260730","first-page":"S0190-9622(26)00388-9","article-title":"Alopecia after GLP-1 agonist therapy: a TriNetX database active comparator retrospective cohort study","author":"Lauck","year":"2026","journal-title":"J Am Acad Dermatol"},{"key":"R15-20260730","doi-asserted-by":"crossref","first-page":"e70163","DOI":"10.1002\/dmrr.70163","article-title":"Not all GLP-1 receptor agonists are alike: Real-world evidence of differential endocrine and dermatologic safety","volume":"42","author":"Lee","year":"2026","journal-title":"Diabetes Metab Res Rev"},{"key":"R16-20260730","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.jaad.2025.08.033","article-title":"Increased risk of telogen effluvium with tirzepatide compared to other weight loss medications: a retrospective cohort TriNetX database study","volume":"93","author":"Neubauer","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"R17-20260730","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1111\/ijd.17971","article-title":"Association between androgenetic alopecia and glucagon-like peptide-1 receptor treatment in type 2 diabetes mellitus patients: a retrospective cohort study","volume":"64","author":"Singal","year":"2025","journal-title":"Int J Dermatol"},{"key":"R18-20260730","doi-asserted-by":"crossref","first-page":"e70835","DOI":"10.1111\/jocd.70835","article-title":"Predictors and characteristics of hair loss among users of GLP-1 receptor agonists: a cross-sectional analysis","volume":"25","author":"Argobi","year":"2026","journal-title":"J Cosmet Dermatol"},{"key":"R19-20260730","doi-asserted-by":"crossref","first-page":"199","DOI":"10.7326\/ANNALS-24-01590","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists for weight loss among adults without diabetes: a systematic review of randomized controlled trials","volume":"178","author":"Moiz","year":"2025","journal-title":"Ann Intern Med"},{"key":"R20-20260730","doi-asserted-by":"crossref","first-page":"e70125","DOI":"10.1111\/jocd.70125","article-title":"Alopecia and semaglutide: connecting the dots for patient safety","volume":"24","author":"Haykal","year":"2025","journal-title":"J Cosmet Dermatol"},{"key":"R21-20260730","doi-asserted-by":"crossref","first-page":"NP809","DOI":"10.1093\/asj\/sjae132","article-title":"Decoding the implications of glucagon-like peptide-1 receptor agonists on accelerated facial and skin aging","volume":"44","author":"Ridha","year":"2024","journal-title":"Aesthet Surg J"},{"key":"R22-20260730","first-page":"77","article-title":"Efficacy of adipocyte-derived stem cells-conditioned media in telogen effluvium","volume":"16","author":"Zari","year":"2023","journal-title":"Stem Cells Cloning"},{"key":"R23-20260730","doi-asserted-by":"crossref","first-page":"130","DOI":"10.2174\/187221312800166859","article-title":"Minoxidil use in dermatology, side effects and recent patents","volume":"6","author":"Rossi","year":"2012","journal-title":"Recent Pat Inflamm Allergy Drug Discov"},{"key":"R24-20260730","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1001\/jamadermatol.2016.5790","article-title":"Interventions for female pattern hair loss","volume":"153","author":"van Zuuren","year":"2017","journal-title":"JAMA Dermatol"},{"key":"R25-20260730","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/jamadermatol.2022.4867","article-title":"Evaluation of the safety and effectiveness of nutritional supplements for treating hair loss: a systematic review","volume":"159","author":"Drake","year":"2023","journal-title":"JAMA Dermatol"},{"key":"R26-20260730","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/skinhd\/vzaf009","article-title":"Can oral minoxidil be the game changer in androgenetic alopecia? A comprehensive review and meta-analysis comparing topical and oral minoxidil for treating androgenetic alopecia","volume":"5","author":"Fazal","year":"2025","journal-title":"Skin Health Dis"},{"key":"R27-20260730","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jdcr.2024.06.001","article-title":"Treatment of insulin resistance with tirzepatide leading to improvement of hair loss","volume":"50","author":"Gordon","year":"2024","journal-title":"JAAD Case Rep"},{"key":"R28-20260730","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.jaad.2025.04.058","article-title":"GLP-1 agonists may modulate treatment efficacy in central centrifugal cicatricial alopecia","volume":"93","author":"Desir","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"R29-20260730","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jacc.2019.11.044","article-title":"Cardiometabolic-based chronic disease, adiposity and dysglycemia drivers: JACC state-of-the-art review","volume":"75","author":"Mechanick","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"R30-20260730","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/j.1463-1326.2007.00818.x","article-title":"Effects of insulin resistance on endothelial function: possible mechanisms and clinical implications","volume":"10","author":"Tousoulis","year":"2008","journal-title":"Diabetes Obes Metab"},{"key":"R31-20260730","first-page":"S0190-9622(26)00263-X","article-title":"Impact of GLP-1 and GLP-1\/GIP agonists on healthcare resource utilization in individuals with scarring alopecias: a retrospective cohort analysis using TriNetX","author":"Hill","year":"2026","journal-title":"J Am Acad Dermatol"},{"key":"R32-20260730","first-page":"e76267","article-title":"Improvement of recalcitrant folliculitis decalvans with tirzepatide: a case report","volume":"16","author":"Morrissette","year":"2024","journal-title":"Cureus"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/DSS.0000000000005176","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T04:03:01Z","timestamp":1785384181000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/DSS.0000000000005176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":32,"journal-issue":{"issue":"6S","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000005176","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"value":"1076-0512","type":"print"},{"value":"1524-4725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]}}}